Updated

Johnson & Johnson is considering the sale of its orthopedics unit, with the deal potentially valued at approximately $20 billion, as the healthcare conglomerate continues its strategic portfolio reshaping. The potential divestiture reflects J&J's broader effort to focus capital on higher-growth areas including pharmaceuticals and consumer health, while testing the market appetite for a standalone orthopedic device business.